Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Pujade-Lauraine

Showing results (1-10 of 151) with videos related to

Pageof 16
Sort By:
Oncology|July 15, 2005
Once-weekly treatment of anemia in patients with cancer: a comparative review of epoetinsEric Pujade-Lauraine, Clare Topham
Oncology|October 19, 2004
The burden of anaemia in patients with cancerEric Pujade-Lauraine, Pere Gascón
Therapeutic Advances in Medical Oncology|June 18, 2019
Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancerJonathan A Ledermann, Eric Pujade-Lauraine
Bulletin Du Cancer|January 7, 2004
[Economic assessment of Caelyx versus topotecan in advanced ovarian cancer]Véronique Girre, Eric Pujade-Lauraine, Isabelle Durand-Zaleski
Bulletin Du Cancer|June 20, 2017
Florence Joly, Denis Querleu, Moise Namer, et al.
Current Opinion in Obstetrics & Gynecology|December 10, 2014
New clinical research strategies for rare gynecologic malignanciesIsabelle Ray-Coquard, Eric Pujade-Lauraine, Jonathan A Ledermann
Critical Reviews in Oncology/Hematology|September 29, 2009
Pegylated liposomal doxorubicin combined with carboplatin: a rational treatment choice for advanced ovarian cancerSandro Pignata, Eric Pujade Lauraine, Andreas du Bois, et al.
Oncology Reports|September 6, 2005
Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practiceEric Pujade-Lauraine, Alain J Richard, Claudine Sapède, et al.
Future Oncology (London, England)|March 28, 2018
Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study designEric Pujade-Lauraine, Keiichi Fujiwara, Samuel S Dychter, et al.
Gynecologic Oncology|April 6, 2016
Prognostic factors for overall survival in elderly patients with advanced ovarian cancer treated with chemotherapy: Results of a pooled analysis of three GINECO phase II trialsFabien Tinquaut, Gilles Freyer, Franck Chauvin, et al.
Pageof 16

Showing results (1-10 of 151) with videos related to

Sort By:
Pageof 16
Oncology|July 15, 2005
Once-weekly treatment of anemia in patients with cancer: a comparative review of epoetinsEric Pujade-Lauraine, Clare Topham
Oncology|October 19, 2004
The burden of anaemia in patients with cancerEric Pujade-Lauraine, Pere Gascón
Therapeutic Advances in Medical Oncology|June 18, 2019
Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancerJonathan A Ledermann, Eric Pujade-Lauraine
Bulletin Du Cancer|January 7, 2004
[Economic assessment of Caelyx versus topotecan in advanced ovarian cancer]Véronique Girre, Eric Pujade-Lauraine, Isabelle Durand-Zaleski
Bulletin Du Cancer|June 20, 2017
Florence Joly, Denis Querleu, Moise Namer, et al.
Current Opinion in Obstetrics & Gynecology|December 10, 2014
New clinical research strategies for rare gynecologic malignanciesIsabelle Ray-Coquard, Eric Pujade-Lauraine, Jonathan A Ledermann
Critical Reviews in Oncology/Hematology|September 29, 2009
Pegylated liposomal doxorubicin combined with carboplatin: a rational treatment choice for advanced ovarian cancerSandro Pignata, Eric Pujade Lauraine, Andreas du Bois, et al.
Oncology Reports|September 6, 2005
Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practiceEric Pujade-Lauraine, Alain J Richard, Claudine Sapède, et al.
Future Oncology (London, England)|March 28, 2018
Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study designEric Pujade-Lauraine, Keiichi Fujiwara, Samuel S Dychter, et al.
Gynecologic Oncology|April 6, 2016
Prognostic factors for overall survival in elderly patients with advanced ovarian cancer treated with chemotherapy: Results of a pooled analysis of three GINECO phase II trialsFabien Tinquaut, Gilles Freyer, Franck Chauvin, et al.
Pageof 16